Emtreo Injection

Introduction

Emtreo is a medication that contains the active ingredient Treosulfan. It is available in the form of an injection and is used for the treatment of certain types of cancer.

Uses

Emtreo is primarily prescribed for the treatment of various types of cancer, including ovarian cancer, breast cancer, and non-Hodgkin lymphoma. It is often used in combination with other chemotherapy medications to help slow down or stop the growth of cancer cells.

Dosage and Administration

The dosage of Emtreo will depend on several factors, such as the type and stage of cancer being treated, the patient’s overall health, and their response to the medication. Follow the instructions provided by your healthcare provider or pharmacist.

Emtreo is administered by a healthcare professional through an intravenous (IV) infusion. The infusion is typically given over a specific period of time, as determined by your healthcare provider. Receive the full prescribed dose and to complete the entire treatment course, unless otherwise instructed by your healthcare provider.

Mechanism of Action

Treosulfan, the active ingredient in Emtreo, works by interfering with the growth and spread of cancer cells. It belongs to a class of medications known as alkylating agents, which work by damaging the DNA within cancer cells, ultimately leading to their death. This mechanism helps to slow down or stop the growth of cancer.

Side Effects

Common side effects may include nausea, vomiting, loss of appetite, fatigue, and hair loss. These side effects are usually temporary and will resolve after treatment is completed. However, if these side effects persist or become severe, notify your healthcare provider.

In some cases, Emtreo may cause more serious side effects, such as allergic reactions, blood disorders, or liver problems. If you experience any unusual symptoms or side effects while receiving this medication, seek immediate medical attention.

Drug Interactions

Emtreo may interact with other medications, including certain chemotherapy drugs or medications that affect the liver. Inform your healthcare provider about all the medications you are currently taking, including prescription, over-the-counter, and herbal products. This will help ensure that any potential drug interactions are identified and managed appropriately.

Precautions

Before receiving Emtreo, inform your healthcare provider about any known allergies, as well as any medical conditions you have, including liver problems or a history of blood disorders. This will help your healthcare provider determine if Emtreo is suitable for you.

Emtreo should not be used during pregnancy, as it may harm the developing fetus. Use effective contraception during treatment and to discuss family planning with your healthcare provider.

Storage

Patient Tips

• attend all scheduled appointments with your healthcare provider for regular check-ups and monitoring during treatment with Emtreo.
• If you experience any side effects or have any concerns while receiving this medication, do not hesitate to contact your healthcare provider for guidance.
• Follow any additional instructions provided by your healthcare provider regarding diet, hydration, and lifestyle modifications during treatment.
• If you miss an appointment or a dose of Emtreo, contact your healthcare provider as soon as possible to reschedule or discuss alternative options.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Trecondi 1g powder for solution for infusion (Health Professionals SmPC) Available at:
• Treosulfan: What is it and is it FDA approved? (Drugs.com) [Accessed 2 Jun. 2024] (online) Available at:
• Slatter MA, Gennery AR. Treosulfan-based conditioning for inborn errors of immunity. Ther Adv Hematol. 2021 May 20;12:20406207211013985. doi: 10.1177/20406207211013985. eCollection 2021. [Accessed 6 Jun. 2024] Available at:
• Lüftinger R, Zubarovskaya N, Galimard JE, Cseh A, Salzer E, Locatelli F, Algeri M, Yesilipek A, de la Fuente J, Isgrò A, Alseraihy A, Angelucci E, Smiers FJ, La La Nasa G, Zecca M, Fisgin T, Unal E, Kleinschmidt K, Peters C, Lankester A, Corbacioglu S; EBMT Pediatric Diseases, Inborn Errors Working Parties. Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major. Ann Hematol. 2022 Mar;101(3):655-665. doi: 10.1007/s00277-021-04732-4. Epub 2022 Jan 9. [Accessed 28 Jun. 2024] Available at: